NewsRoom Articles - BioMedWire (BMW)

MondayAug 10, 2026 4:33 pm

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit the risk of contracting a bacterial infection that has surged around the region. The flesh-eating bacteria become especially prevalent during summer in coastal water. In a press release, health authorities in Louisiana revealed that so far, nine cases of the infection have been confirmed and five of the affected people have lost their lives. The state added that over the past 10 years, about seven cases of Vibrio vulnificus infections were confirmed annually. Given that the summer is still on, confirmed infections could rise even…

FridayAug 07, 2026 10:00 am

Spanish Patient Highlights Risks of Poorly Cooked Pork

Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and was treated as such, but additional tests brought to light a scarier cause of his illness: cysts resulting from a pork tapeworm infection. This case highlights the dangers of exposure to these worms, or eating pork that hasn’t been cooked fully. The patient’s medical mystery started with worsening headaches that lasted more than two weeks. His behavior also started changing in subtle ways, and these symptoms prompted him to visit his doctor. A CT scan conducted on his brain showed he had lesions, and the doctor feared that he had cancer that…

ThursdayAug 06, 2026 10:00 am

Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients

While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients that initially respond well end up becoming unresponsive. Scientists have been working to develop tools that can help in predicting which patients are likely to benefit from immunotherapy, and a new liquid biopsy has provided a simpler way to do just that for patients with advanced lung cancer. According to a study that was published in the journal Clinical Cancer Research, a team at the Kimmel Cancer Research Center at Johns Hopkins together with their collaborators was able to develop a liquid biopsy that can accurately predict which patients will benefit from immunotherapy against…

WednesdayAug 05, 2026 2:40 pm

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%. The company is advancing commercialization through scalable manufacturing, surgeon training programs, and continued U.S. Phase III clinical progress. These developments reinforce Regentis' strategy of bringing innovative cartilage repair technology from clinical validation to commercial scale, with unit economics that improve as production volumes build. Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, its innovative cell-free hydrogel implant for focal knee cartilage repair, with a value proposition that extends across the entire healthcare ecosystem. Designed to simplify treatment while improving clinical outcomes,…

WednesdayAug 05, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb. OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs. VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.…

TuesdayAug 04, 2026 10:00 am

As Cases of Measles Rise, US Officials Double Down on Contact Tracing and Vaccination

As July came to an end, the United States reached an undesirable milestone: exceeding the total number of confirmed cases of measles recorded in 2025. The current case count (2,371 individuals) makes it the highest tally recorded in three decades. This tally comes as clusters of infection are recorded in Utah, South Carolina and Arizona. While just a few states have recorded confirmed cases of this infection, the overriding fear is that outbreaks of this disease could occur in other states as well since the infection can spread rapidly. The experience of Delaware gives proof of this concern. In July,…

FridayJul 31, 2026 10:00 am

Climate Change is Accelerating the Spread of Infectious Diseases, Experts Warn

Scientists and public health experts are warning that climate change is accelerating the rate at which infectious diseases spread, and policymakers don’t seem to be taking this threat as seriously as they should. A sobering example is the 14 million cases of dengue fever that were recorded globally in 2024. This figure was double what had been documented in 2023, 7 million cases. A major contributor to this spike was the El Niño weather that occurred around that time. That spike in dengue cases was alarming, and it was also a warning sign that as the planet continued warming up, many more such massive outbreaks of infectious diseases…

ThursdayJul 30, 2026 10:00 am

Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment

Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months from the time they are diagnosed with the malignancy. Existing treatments like surgery, chemotherapy and radiotherapy aren’t effective in halting the progression of this disease. Now, a new study shows that an experimental therapy containing vitamin B12 could halt GBM in its tracks. The study was conducted by a team at the Taussig Cancer Center of the Cleveland Clinic Foundation together with Nitric Oxide Services LLC. The researchers investigated a vitamin B12 compound called NO-Cbl (nitrosylcobalamin). This modified type of vitamin B12 releases nitric oxide. The purpose of the preclinical study was to look into whether this compound could…

WednesdayJul 29, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. Recent regulatory feedback from Germany's Paul-Ehrlich-Institute has provided additional clarity for development of the company's lead BiTAC(R)-TCE program. Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics…

TuesdayJul 28, 2026 11:15 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization. Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair. GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes. Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address…